Utilization study of filgrastim (Neutromax®) during autologous haematopoietic precursor transplantation for myeloma and lymphoma patients

被引：13

作者：

Ferro, Hugo H. ^{[1
]}

Juni, Mariana ^{[2
]}

Bello, Ricardo ^{[1
]}

Vidal, Alejandro ^{[1
]}

Diez, Roberto A. ^{[1
]}

Pavlovsky, Santiago ^{[2
]}

机构：

[1] Bio Sidus SA, RA-1254 Buenos Aires, DF, Argentina

[2] Fundaleu, Buenos Aires, DF, Argentina

来源：

TRANSFUSION AND APHERESIS SCIENCE | 2009年 / 41卷 / 02期

关键词：

PROGENITOR-CELL TRANSPLANTATION; COLONY-STIMULATING FACTOR; RANDOMIZED-TRIAL; G-CSF; RECOVERY; CHEMOTHERAPY; MALIGNANCIES; EXPERIENCE; AUTOGRAFT;

D O I：

10.1016/j.transci.2009.07.007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To describe utilization of a biosimilar product containing filgrastim (Neutromax (R)), data of 414 myeloma or lymphoma patients subjected to autologous SCT between 1998 and 2007 were analyzed. Filgrastim was used for mobilization of progenitors (5 days at 300 mu g/day) and for the recovery of neutropenia after transplantation (100 mu g/day, since day +5). In 2003, the excipient mannitol was replaced by sorbitol. A mean dose of 9.47 x 10(6) CD34(+) cells/kg was infused; 100 neutrophils/mm(3) required 5-day treatment; 500 neutrophils/mm(3), 6 days and 1000 neutrophils/mm(3), 7 days. Neutromax (R) effect in SCT is similar to reports with other brands. No difference was found between formulations. (C) 2009 Elsevier Ltd. All rights reserved.

引用

收藏

页码：87 / 93

页数：7

相关论文

共 17 条

[1] Autologous peripheral blood stem cell transplantation for multiple myeloma:: a report of 259 cases from the Spanish registry [J].

Alegre, A ;

Díaz-Mediavilla, J ;

San-Miguel, J ;

Martínez, R ;

Laraña, JG ;

Sureda, A ;

Lahuerta, JJ ;

Morales, D ;

Bladé, J ;

Caballero, D ;

De la Rubia, J ;

Escudero, A ;

Díez-Martín, JL ;

Hernández-Navarro, F ;

Rifón, J ;

Odriozola, J ;

Brunet, S ;

De la Serna, J ;

Besalduch, J ;

Vidal, MJ ;

Solano, C ;

Leon, A ;

Sánchez, JJ ;

Martínez-Chamorro, C ;

Fernández-Rañada, JM .

BONE MARROW TRANSPLANTATION, 1998, 21 (02) :133-140

[2]

[Anonymous], 2007, R LANG ENV STAT COMP

[3] A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation [J].

Bence-Bruckler, I ;

Bredeson, C ;

Atkins, H ;

McDiarmid, S ;

Hamelin, L ;

Hopkins, H ;

Perry, G ;

Genest, P ;

Huebsch, L .

BONE MARROW TRANSPLANTATION, 1998, 22 (10) :965-969

[4] Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial [J].

Bolwell, BJ ;

Pohlman, B ;

Andresen, S ;

Kalaycio, M ;

Goormastic, M ;

Wise, K ;

Wakeling, A ;

Dannley, R ;

Overmoyer, B .

BONE MARROW TRANSPLANTATION, 1998, 21 (04) :369-373

[5] Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation [J].

Dekker, Allison ;

Bulley, Sean ;

Beyene, Joseph ;

Dupuis, L. Lee ;

Doyle, John J. ;

Sung, Lillian .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (33) :5207-5215

[6] WHERE DO WE STAND WITH RESPECT TO THE USE OF PERIPHERAL-BLOOD PROGENITOR CELLS [J].

GIANNI, AM .

ANNALS OF ONCOLOGY, 1994, 5 (09) :781-784

[7]

HARRIS NL, 1994, BLOOD, V84, P1361

[8] World Health Organization Classification of lymphomas:: A work in progress [J].

Jaffe, ES ;

Harris, NL ;

Diebold, J ;

Müller-Hermelink, HK .

ANNALS OF ONCOLOGY, 1998, 9 :25-30

[9] Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit [J].

McQuaker, IG ;

Hunter, AE ;

Pacey, S ;

Haynes, AP ;

Iqbal, A ;

Russell, NH .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :451-457

[10]

Milone GA, 2000, MEDICINA-BUENOS AIRE, V60, P115